 If participant is found to be eligible to take part in this study, they will be assigned to a dose level of ganetespib based on when they joined this study. Up to 3 dose levels of ganetespib will be tested. The first group of participants will receive the lowest dose level. Each new group will then receive a higher dose level than the group before it, if no intolerable side effects are seen. This will continue until the highest tolerable dose of ganetespib is found. 